When does Ganirelix patent exclusivity expire?
The patent exclusivity for Ganirelix is set to expire in 2027, according to DrugPatentWatch.com [1].
What happens after Ganirelix patent expiration?
Following the expiration of patent exclusivity, generic versions of Ganirelix may become available. This typically leads to increased competition and potentially lower prices for the medication.
How does Ganirelix work?
Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist. It works by suppressing the premature surge of luteinizing hormone (LH) that can occur during controlled ovarian stimulation, a process used in assisted reproductive technologies like in-vitro fertilization (IVF) [2].
Who makes Ganirelix?
Ganirelix is manufactured by Merck & Co. It is marketed under the brand name Antagon [3].
What are the risks associated with Ganirelix?
The use of Ganirelix is associated with potential side effects, including headache, nausea, and injection site reactions. More serious risks, though less common, can also occur [2].
What is the competition for Ganirelix?
Other GnRH antagonists and agonists are used in assisted reproduction. These drugs offer alternative mechanisms for controlling ovulation timing in IVF cycles [2].
How is Ganirelix administered?
Ganirelix is administered via subcutaneous injection [2].
What clinical data supports Ganirelix use?
Clinical trials have demonstrated the efficacy of Ganirelix in preventing premature LH surges during ovarian stimulation, thereby improving outcomes in IVF cycles [2].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugs.com/ganirelix.html
[3] https://www.merck.com/